u/medicaltourissm

This distinction often gets lost in news headlines.

A patient may achieve complete remission, meaning no detectable signs of cancer using current tests.

That doesn't necessarily mean the disease has been cured.

Some cancers remain in remission for years.

Others relapse despite an excellent initial response.

That's why long-term follow-up is so important when evaluating new therapies.

When you read headlines about a "breakthrough," do you usually check how long patients were followed before the conclusions were drawn?

[ Removed by Reddit on account of violating the content policy. ]

[ Removed by Reddit on account of violating the content policy. ]

[ Removed by Reddit on account of violating the content policy. ]

I remember the first time a patient told me: "The CAR-T worked perfectly. I was in remission for 8 months. Then... it came back."

She was devastated. Her doctor said the cancer had become "CD19-negative." The CAR-T cells—trained to hunt CD19—were now blind.

She thought she was out of options.

She wasn't.

What is CD19-negative relapse?

CAR-T therapy for blood cancers usually targets a protein called CD19. It's like a flag on cancer cells. CAR-T cells find the flag and destroy the cell.

But cancer is smart.

In about 10-20% of patients, cancer cells learn to lower the CD19 flag. They become invisible. The CAR-T cells swim right past them. This is called "antigen escape."

What happens next?

Most patients are told: "We've done all we can."

But there are options emerging:

1. CD22-targeted therapy. CD22 is another flag on B-cell cancers. Inotuzumab Ozogamicin (Besponsa) is an FDA-approved drug that delivers a chemotherapy payload directly to CD22-positive cells. It's not CAR-T—it's a "smart bomb." Clinical trials showed ~80% complete remission in relapsed patients.
2. CD22 CAR-T. Still in clinical trials, mostly in China. Early results are promising for patients who failed CD19 CAR-T.
3. Dual-targeting CAR-T. This is the next generation. CAR-T cells engineered to recognize BOTH CD19 and CD22 simultaneously. If the cancer drops one flag, the other is still visible. Think of it as a missile with two guidance systems. Clinical trials are active in China (Phase I/II).

What about cost?

• Inotuzumab (Besponsa): Available globally, price varies by country
• CD22 CAR-T (China): ~$40,000-60,000 (clinical trials)
• Dual-targeting CAR-T (China): ~$50,000-70,000 (clinical trials)

I run a small platform that helps patients navigate these options. I'm not a doctor. I don't charge patients. I just help people figure out where to go and what questions to ask.

If you've relapsed after CAR-T, ask me anything. There may be roads you haven't seen yet.